| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Chief Financial Officer | Common Stock | 42,165 | $158,962 | $3.77 | 23 May 2023 | Direct |
| Prelude Therapeutics Inc | Chief Financial Officer | Employee Stock Option (right to buy) | 150,000 | 01 Mar 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 01 Mar 2024 | 1 | $0 | 4 | Chief Financial Officer | 04 Mar 2024, 18:04 |
| PRLD | Prelude Therapeutics Inc | 23 May 2023 | 1 | +$27,500 | 4 | Chief Financial Officer | 25 May 2023, 16:05 |
| PRLD | Prelude Therapeutics Inc | 07 Feb 2023 | 1 | $0 | 4 | Chief Financial Officer | 09 Feb 2023, 15:07 |
| PRLD | Prelude Therapeutics Inc | 21 Dec 2022 | 1 | $0 | 4 | Chief Financial Officer | 22 Dec 2022, 15:05 |
| PRLD | Prelude Therapeutics Inc | 08 Dec 2022 | 1 | +$47,600 | 4 | Chief Financial Officer | 12 Dec 2022, 08:13 |
| PRLD | Prelude Therapeutics Inc | 01 Jun 2022 | 1 | +$42,300 | 4 | Chief Financial Officer | 01 Jun 2022, 16:31 |
| PRLD | Prelude Therapeutics Inc | 21 Mar 2022 | 1 | +$48,815 | 4 | Chief Financial Officer | 22 Mar 2022, 18:01 |
| PRLD | Prelude Therapeutics Inc | 15 Feb 2022 | 1 | $0 | 4 | Chief Financial Officer | 17 Feb 2022, 18:11 |
| PRLD | Prelude Therapeutics Inc | 13 Dec 2021 | 1 | +$61,400 | 4 | Chief Financial Officer | 14 Dec 2021, 16:37 |
| PRLD | Prelude Therapeutics Inc | 29 Nov 2021 | 1 | $0 | 4 | Chief Financial Officer | 01 Dec 2021, 17:00 |
| PRLD | Prelude Therapeutics Inc | 29 Nov 2021 | 0 | $0 | 3 | Chief Financial Officer | 01 Dec 2021, 16:56 |